Psyence Biomedical (PBM) vs Universe Pharmaceuticals (UPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Universe Pharmaceuticals (UPC) has outperformed Psyence Biomedical (PBM) over the past year, losing 55.8% versus a loss of 97.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBM | UPC |
|---|---|---|
| Share price | $4.97 | $4.15 |
| Market cap | — | $20.85M |
| 1-day change | -2.93% | 0.00% |
| YTD return | -82.59% | +9.71% |
| 1-year return | -97.05% | -55.81% |
| 5-year return | — | -99.95% |
| EPS (TTM) | $-12.56 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $150.78 | $17.96 |
| 52-week low | $1.92 | $2.00 |
| Distance from 52-week high | -96.70% | -76.89% |
| Average volume | 94.85K | 788.87K |
| Shares outstanding | — | 5.01M |
| Employees | 12 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UPC has outperformed PBM by 41.2 percentage points over the past year.
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Universe Pharmaceuticals
UPC stock →Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
PBM vs UPC FAQ
Which stock has performed better over the past year, PBM or UPC?
UPC returned -55.81% over the past 12 months, compared with -97.05% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Psyence Biomedical and Universe Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.